Company Announcements

Publication of Supplementary Prospectus

Source: RNS
RNS Number : 2401D
Natwest Markets PLC
17 February 2020

NatWest Markets Plc

Publication of Supplementary Prospectus

The following supplementary prospectus has been approved by the Financial Conduct Authority and is available for viewing:

Supplementary Prospectus to (i) the NatWest Markets Plc £10,000,000,000 Euro Medium Term Note Programme and (ii) the NatWest Markets Plc £5,000,000,000 Structured Debt Issuance Programme, dated 17 February 2020. 

To view the full documents, please paste the following URL into the address bar of your browser:

A copy of the above Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

For further information, please contact:

Amanda Hausler

Head of NatWest Markets Investor Relations

Tel: +44 (0) 207 085 6448



Anthony Everill

Head of Capital Markets & Funding, NatWest Markets

Tel: +44 (0) 203 361 7679



Please note that the information contained in the Supplementary Prospectuses (and the Prospectus to which it relates) may be addressed to and/or targeted at persons who are residents of particular countries (specified in the relevant Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the relevant Prospectus and the Supplementary Prospectuses is not addressed. Prior to relying on the information contained in the relevant Prospectus and the Supplementary Prospectuses you must ascertain from the relevant Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.


Legal Entity Identifier: 

NatWest Markets Plc - RR3QWICWWIPCS8A4S074

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit